



**Biomax News • Biomax News • Biomax News •
FOR IMMEDIATE RELEASE**

Contact:

Dr. Dieter Maier
Biomax Informatics AG
Robert-Koch-Str. 2
D-82152 Planegg
Germany
Tel: +49 89 895574-0
Fax: +49 89 895574-825
Website: www.biomax.com

BIOMAX INFORMATICS AG establishes knowledge management environment for modeling airway diseases and improving patient outcomes

PLANEGG, Germany — (18 July 2012) — Participating in the European AirPROM project to unravel the complexity of airway diseases and improve personalized healthcare, Biomax has built the knowledge management infrastructure to facilitate the information flow within AirPROM. Using a systems biology approach, the AirPROM consortium aims to develop validated computational models to predict airway disease progression and responses to therapy and elucidate the relationships between clinical phenotype, genotype, airway structure and physiology.

Leveraging Biomax's BioXM technology, a comprehensive airway disease knowledge base for the entire AirPROM consortium is being established. The BioXM system provides a secure and sustainable infrastructure that semantically integrates the clinical, physiological, genetic, and experimental data produced with existing biomedical knowledge from allied consortia and public databases. This resource will be available for analysis and modeling, and will facilitate sharing, collaboration and publication within AirPROM and beyond.

"The AirPROM project epitomizes the new era of predictive, personalized healthcare," says Biomax Project Manager, Dr. Dieter Maier. "It embraces state-of-the-art clinical, imaging, 'omic,' computational modeling and bioengineering technology, but goes beyond this to integrate cutting-edge platforms for high-throughput analysis of patient-specific data captured by imaging with clinical and physiological phenotypes. By involving clinicians from the beginning of the project, we will develop patient-specific models that truly impact personalized medicine."

Airway diseases are among the leading causes of healthcare costs in Europe. Recent developments in CT scanning and functional imaging have improved the analysis of patient-specific airway physiology and disease progression. Several new pharmacological therapies and novel devices for surgical therapy are in development. While these advances provide an opportunity for improved outcomes, they are highly selective and expensive; the challenge is to find the right therapy for the individual patient. AirPROM aims to provide the critical tool to help healthcare providers make the best, well-informed decisions.

About AirPROM

The AirPROM consortium is funded by the 7th Framework Program of the European Commission to develop an integrated multi-scale airway disease model. The AirPROM consortium brings together existing consortia (U-BIOPRED IMI, EvA FP7 and BTS severe asthma) and 34 academic and industry partners. More information is available at <http://www.airprom.european-lung-foundation.org>

About Biomax

Biomax Informatics AG (Planegg, Germany), founded in 1997, is a leader in the development of computational solutions for the life sciences. Biomax developed the BioXM™ Knowledge Management Environment and markets the Viscovery® technology for better decision-making and knowledge management in biomedical sciences. More information about Biomax is available at www.biomax.com.

###